Omnes in talks to buy BioFutur

The GP's mid-market team is in charge of the transaction, Unquote has learned. The team invests via Omnes Croissance 4, which closed on €210m in 2017. The fund targets French SMEs with a turnover that falls within the €25-180m range, investing equity tickets of €8-25m.

The GP regularly backs healthcare companies via early-stage, growth and buyout transactions, and in 2019 alone it invested in France-based NH TherAguix and Biosency, Italy-based Newronika, Austria-headquartered Themis and Belgium-based AgomAb Therapeutics.

Omnes declined to comment on the transaction. 

Company 
Based in Meaux, BioFutur operates 51 laboratories in the greater Paris area, employing 500 people. The company, which is owned by 10 biologists, generates €60m in revenues and €5m in EBITDA, according to a report by French publication Capital Finance.

People 
Omnes Capital – Benjamin Arm (managing partner). 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• France
• Healthcare
• France
• Omnes Capital